Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Botanix Pharmaceuticals Ltd (Botanix) is a pharmaceutical company that develops next-generation dermatological treatments. The company's main activities include conducting clinical research and commercializing dermatological therapies. Botanix's major products include sofpironium topical gel for axillary hyperhidrosis, BTX 1503 for severe acne, BTX 1702 for rosacea, BTX 1204A for atopic dermatitis, and BTX 1801 for antimicrobial. It markets its sofpironium topical gels under the Sofdra brand name. The company's products serve patients in the human and animal health sectors. It operates in the US and Australia. Botanix is headquartered in Perth, Western Australia, Australia.
Headquarters
Australia
Address
Suite 3, 41-47 Colin Street, West Perth, Western Australia, 6005
Website
www.botanixpharma.com
Telephone
61 8 62850083
No of Employees
50
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BOT (ASX)
Revenue (2025)
$3.8M
856.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-522.9%
(2025 vs 2024)
Market Cap*
$45.5M
Net Profit Margin (2025)
XYZ
34.9%
(2025 vs 2024)
* As of and is in US$
Botanix Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Sofdra |
| Sofpironium Bromide: Axillary Hyperhidrosis (Excessive Underarm Sweating) | |
| BTX1503: Moderate to Severe Acne | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Botanix Pharmaceuticals Ltd | Mayne Pharma Group Ltd | Melodiol Global Health Ltd | Cann Group Ltd | Acrux Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Perth | Adelaide | Perth | Port Melbourne | Melbourne |
| State/Province | Western Australia | South Australia | Western Australia | Victoria | Victoria |
| No. of Employees | 50 | 450 | - | 40 | 43 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vincent Ippolito | Chairman | Executive Board | 2019 | - |
| Howard McKibbon | Chief Executive Officer | Senior Management | 2023 | - |
| Graeme Morissey | Chief Financial Officer | Senior Management | 2024 | - |
| David Morgan | Head - Corporate Affairs | Senior Management | - | - |
| Boris Meyerson | Chief Business Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer